LATUDA® is now available as médicament d’exception for the management of depressive episodes of bipolar I disorder.
Read more
IMPORTANT UPDATE!
Please be advised that during the first half of 2017 there will be some changes to the availability of NIASPAN® (500mg & 1000mg) and NIASPAN FCT® (750mg).
Read more
IMPORTANT INFORMATION
TEMPORARY SHORTAGE OF LOVENOX® IN MULTIDOSE VIAL
(ENOXAPARIN SODIUM)
Sanofi-aventis Canada Inc. would like to inform you that due to a supply delay, LOVENOX 300 mg/3 mL multidose vials will be on temporary backorder by the third week of October.
Read more
IMPORTANT INFORMATION!
Effective November 1st, 2016, Merck Canada will transfer the marketing authorization of COSOPT®, TIMOPTIC®, TIMOPTIC-XE® and TRUSOPT® to Purdue Pharma Canada.
Read more
